Medication info

Hulica Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Hubist Pharmaceutical Co., Ltd.
Appearance
Hard capsule with brown upper and white lower parts containing white powder
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Expired

MFDS item code 201907779 · Approved 2019.11.06

This product's status changed to Expired on 2024.11.06. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of epilepsy (partial seizures), treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This drug is administered orally as pregabalin in 2 divided doses per day, with or without food. Since this drug is eliminated primarily by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5. Patients with renal impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this drug may be 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The starting dose of this drug may be 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4. Discontinuation). 2. Epilepsy Adults: The starting dose of this drug may be 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is eliminated primarily by the kidneys as unchanged drug. The clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above equation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Dosage regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: A supplemental dose is an additional dose administered as a single dose. 6. Patients with hepatic impairment No dosage adjustment is required in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Administration is not recommended in children under 12 years of age or adolescent patients 12-17 years of age because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Hubist Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of epilepsy (partial seizures), treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures with secondary general symptoms
  • partial seizures without secondary general symptoms
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunct in patients with epilepsy experiencing partial seizures and can be effective even when secondary general symptoms are not present in some patients. Additionally, it helps alleviate symptoms of fibromyalgia. In other words, it is used to improve neuralgia, epilepsy, and myalgia.

How to take

Adult dose

This drug is administered orally as pregabalin in 2 divided doses per day, with or without food. Since this drug is eliminated primarily by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5. Patients with renal impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this drug may be 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The starting dose of this drug may be 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4. Discontinuation). 2. Epilepsy Adults: The starting dose of this drug may be 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is eliminated primarily by the kidneys as unchanged drug. The clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above equation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Dosage regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosage regimen. b: A supplemental dose is an additional dose administered as a single dose. 6. Patients with hepatic impairment No dosage adjustment is required in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Administration is not recommended in children under 12 years of age or adolescent patients 12-17 years of age because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, if you notice any abnormal changes in mood or behavior while taking it, you should consult a doctor immediately. Individuals allergic to pregabalin or any ingredient of this medication should not take it, and caution is also necessary for patients with lactose intolerance. Diabetic patients may need to adjust the dosage of blood glucose-controlling medication due to weight gain, so they should consult with their doctor. If symptoms of angioedema occur, stop taking the medication immediately and notify medical personnel. Elderly patients should be especially cautious at the beginning of treatment as they are at a higher risk of falling due to dizziness or drowsiness. Notify a doctor if you experience blurred vision or changes in eyesight, as discontinuing the medication may improve the symptoms. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so dosage adjustments should be made according to a doctor's instructions. As there is a risk of drug abuse, patients with mental health issues or a history of drug abuse must consult before administration. Patients with decreased renal function may require dosage adjustments. Patients with heart disease should exercise caution when taking this medication, especially those with heart failure who should discuss it with their doctor. When taken with opioid analgesics, the risk of central nervous system depression may increase, so caution is advised. Patients with respiratory or nervous system diseases, kidney disorders, and elderly patients may face a risk of severe respiratory depression, necessitating potential dose adjustments. During early pregnancy, there is a risk of fetal malformations; therefore, women who are pregnant or planning to become pregnant should discuss with their doctor before taking this medication and should use effective birth control. Breastfeeding women should consult their doctor about whether to discontinue breastfeeding or the medication since this drug can pass into breast milk and affect the child. Before driving or operating hazardous machinery, ensure that this medication does not cause dizziness or drowsiness. Severe skin reactions may rarely occur; if any abnormal skin symptoms arise, stop taking the medication immediately and inform your physician. In case of overdose, symptoms such as mental confusion, drowsiness, and depression may occur, and treatment such as dialysis may be necessary.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, pain, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, nasopharyngitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, derealization, genital hypersensitivity, agitation, mood swings, low affect, high affect, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, abnormal motor coordination, balance disorder, amnesia, attention deficit, memory impairment, tremors, speech disorder, sensory disturbances, sensory loss, sedation, drowsiness, cognitive impairment, nystagmus, language disorder, myoclonus, decreased reflexes, motor abnormalities, psychomotor agitation, positional vertigo, hypersensitivity, burning sensation, tremor at rest, syncope, confusion, hypokinesia, olfactory disturbances, taste loss, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, eye swelling, decreased vision, eye pain, eye strain, increased tear production, eye irritation, mydriasis, change in depth perception during vibration, strabismus, brightness of vision, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urine output, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling drunk, sensory disturbances, fatigue, tightness in the chest, systemic edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, malaise, delirium, paralysis, affective disorder, excitement, seizures, shock, anaphylaxis-like symptoms, skin and mucous membrane syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. The recommended storage temperature is between 15°C and 30°C. This will help maintain the safety and efficacy of the drug.

Appearance and packaging

Appearance

Hard capsule with brown upper and white lower parts containing white powder

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.